Institute for International Research

Special Offer for "Virtual", Start-up and Emerging Companies As part of IBC's ongoing effort to support the initiatives of small and emerging companies, a limited number of reduced rate passes will be made available to "virtual", start-up and emerging companies to attend this conference. For eligibility criteria and to apply for one of these passes, please contact Michael Keenan at mkeenan@ibcusa.com. Filling the Gap between Chemistry & Clinical Integrated R&D to Extend Your R&D Bandwidth Evolving Deal Structures and Business Models Risk-Sharing and Emerging Innovation Evaluating Capabilities and Companies in Asia Practical Experiences, not Honeymoon Stories Event Features Interactive Roundtables Company Showcase Online Partnering Tool Networking Dinner

What is the role of India and China in your global R&D and market strategy?

Over 20 exciting sessions at this comprehensive event will allow you to...

Accelerate your R&D by Implementing an India-China Strategy

• Novartis' R&D center in Shanghai & AstraZeneca's integrated APAC strategy
• Allergan's developing strategy for clinical trials
• Wall Street's view on the migration of R&D to Asia

Hear Scientific Case Studies of Accelerating a Drug Pipeline

• Generating IP on a metabolic disease target in India - Forest and Aurigene
• Developing a novel cancer drug in China - SuperGen and CrownBio-Tigermed
• Project management for CMC tasks toward IND filing in China - Ascenta Therapeutics

Learn Real Stories of Practical Experiences Managing Global Projects

• Evaluating cost, quality and risks in pre/nonclinical CROs/CMOs - Synta Pharmaceuticals
• Sourcing, leveraging and managing R&D partnering/licensing deals - Immusol, Inc.
• Leveraging India/China Partnerships in eADME and Toxicology - Amgen

Increase Partnering Opportunities with New Deal & Risk-Share Models

• Merck's approach to expanding R&D "bandwidth" on specific targets/therapeutic areas
• The Lilly-Hutchison Medipharma risk-share deal
• GSK's CEEDD partnerships from target to clinical POC

Evaluate Emerging Innovation & Integrated R&D Players

• A survey of Chinese innovation and scientific institutions
• Identifying lead compounds from TCM-based natural product libraries
• NCE drug discovery in India - Dr. Reddy's, Orchid, Zydus

Testimonials from 2007 event

"Provided an excellent review of this dynamic and rapidly evolving marketplace. Good set of speakers with clear, tailored presentations."
- Ramesh Subramanian, Chemizon, Inc.

"Addressed many issues associated within the changing landscape of outsourcing... companies, technologies, offerings, perspectives, and business models."
- Richard Soll, TargeGen

"Some very good and highly relevant presentations revealing real experiences. The panel discussions were very well organized and led."
- T. A. Zaleski, Xenotech

"As three-year old start-up discovery service company CEO, I benefited a lot with outstanding presentations. Quality of the presentations was superb."
- Raj (SB) Rajur, CreaGen Biosciences, Inc.

"Great to see and hear how other companies are creatively outsourcing."
- Shawn Melton, Nektar Therapeutics